

PRODUCT INFORMATION



Iopromide

Item No. 18470

CAS Registry No.: 73334-07-3

Formal Name: N¹,N³-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N¹-methyl-1,3-benzenedicarboxamide

Synonym: Ultravist

MF: C₁₈H₂₄I₃N₃O₈

FW: 791.1


Purity: ≥98%

UV/Vis.: λ_{max}: 241 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Iopromide is supplied as a crystalline solid. A stock solution may be made by dissolving the iopromide in the solvent of choice. Iopromide is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of iopromide in these solvents is approximately 10 and 3 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of iopromide can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of iopromide in PBS, pH 7.2, is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Iopromide is a non-ionic, water-soluble X-ray contrast agent for intravascular administration.^{1,2} Iopromide can cause acute kidney injury and is used in animal models of contrast-induced nephropathy.^{3,4}

References

1. Ahn, Y.-H., Koh, Y.-I., Kim, J.-H., *et al.* The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity. *J. Korean Med. Sci.* **30**(3), 245-251 (2015).
2. Park, J.-Y., Lee, S.-K., Kim, J.-Y., *et al.* A new micro-computed tomography-based high-resolution blood-brain barrier imaging technique to study ischemic stroke. *Stroke* **45**(8), 2480-2484 (2014).
3. Hassan, K. and Fadi, H. Is hypoalbuminemia a prognostic risk factor for contrast-induced nephropathy in peritoneal dialysis patients? *Ther. Clin. Risk Manag.* **10**, 787-795 (2014).
4. Wang, N., Wei, R., Li, Q., *et al.* Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism. *Med. Sci. Monit.* **21**, 2886-2892 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM